Copayment vouchers increase adherence to P2Y12 inhibitors

January 2019, Volume 820, Issue 1, pp 10–10 | Cite as

Clinical study

First Online: 26 January 2019

This is a preview of subscription content, to check access.

References

1.
Wang TY, et al. Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. JAMA: the Journal of the American Medical Association 321: 44-55, No. 1, Jan 2019. Available from: URL: http://doi.org/10.1001/jama.2018.19791Google Scholar
2.
Jackevicius CA, et al. Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction. JAMA: the Journal of the American Medical Association 321: 37-39, No. 1, 1 Jan 2019. Available from: URL: http://dx.doi.org/10.1001/jama.2018.20396Google Scholar